Ovagen Research Overview (also known as Ovagen (EDL), Liver & GI Bioregulator, Glu-Asp-Leu Tripeptide)
A synthetic tripeptide bioregulator (Glu-Asp-Leu / EDL) from the Khavinson family, targeting liver and GI tissue through proposed chromatin decondensation, gene activation, and cytoprotective pathways in hepatocytes and GI epithelial cells. Russian studies report improvements in ALT/AST markers, hepatocyte protein synthesis, and digestive function. Standard protocol is 0.8–2.0 mg/day SubQ or 25–50 mg oral, in 30-day cycles repeated 1–2× per year. FDA Category 2 bulk drug substance — no human RCTs; all peptide-format applications are RUO.
What Is Ovagen?
Ovagen is a synthetic tripeptide bioregulator with the sequence Glu-Asp-Leu (EDL), developed at the St. Petersburg Institute of Bioregulation and Gerontology as a liver and gastrointestinal (GI)-targeted member of the Khavinson bioregulator family. It was originally derived from liver tissue extracts and later synthesized as a defined three-amino-acid compound (MW ≈ 375.37 g/mol).
Like other Khavinson peptides, Ovagen is proposed to interact with DNA/chromatin regulatory regions in tissue-specific cells — hepatocytes and GI epithelial cells — to normalize age-related changes in gene expression, support detoxification, and promote cellular repair under toxic or oxidative stress. It is available in two formats: RUO lyophilized peptide vials (SubQ or in-vitro use) and Cytogen oral capsules/drops (supplement format).
Most published research is Russian, small-sample, and preclinical. The FDA classifies Ovagen as a Category 2 bulk drug substance — compounded medication use is prohibited in the US. Western-style RCTs are absent. All peptide-format vendor products are sold for research use only (RUO).
Mechanism of Action
Chromatin and gene-regulation effects: Ovagen is proposed to interact with DNA regulatory regions in hepatocytes and GI epithelial cells, modulating chromatin structure (de-heterochromatinization) analogously to other Khavinson peptides. This would restore gene accessibility and transcriptional profiles associated with healthy liver and GI function, and support genomic stability under toxic or aging-related stress. English-language mechanistic publications are limited; most evidence is theoretical, derived from Khavinson framework studies and parallels with Livagen and Epitalon.
Hepatic and GI tissue support: RUO and Cytogen sources describe Ovagen as promoting hepatocyte regeneration, normalizing protein synthesis, improving metabolic handling of toxins, and stabilizing GI mucosal integrity. Russian before/after studies report normalization of liver enzyme markers (ALT/AST) and improved detoxification capacity. Roles in angiogenesis, collagen synthesis, and cytoprotective pathways in liver, kidney, and epithelial cells have been described — all evidence is preclinical or observational.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
Liver Support & Detoxification
RUO and Cytogen sources report Ovagen supports liver cell regeneration, protein synthesis, and recovery from toxic damage or hepatitis. Small Russian studies claim improvements in ALT/AST enzyme markers and enhanced detoxification capacity. Not validated in Western-style controlled trials.
GI Mucosa & Digestive Function
Ovagen is positioned as a GI mucosal bioregulator supporting digestive tract regeneration, epithelial integrity, and improved digestive function. Particularly relevant where liver-GI interplay underlies metabolic or toxic load scenarios.
Cellular Aging & Genomic Regulation
Khavinson literature and modern RUO commentary frame Ovagen as a research tool for cellular aging, genomic stability, and epigenetic regulation in liver, kidney, and epithelial cells. Over 200 published studies touch on Ovagen, mostly preclinical, with robust human data lacking.
Cytoprotection under Toxic Stress
In-vitro studies describe Ovagen stabilizing cellular activity during toxic load experiments and supporting epithelial recovery. Conceptual applications include recovery from hepatotoxic drug exposure, oxidative stress, and chemical insult in research models.
Research Protocols (Educational Only)
Disclaimer — RUO / Russian Literature Only
These protocols reflect Russian bioregulator practice, Cytogen guidance, and RUO discussion — not validated medical regimens. The FDA classifies Ovagen as a Category 2 bulk drug substance; compounded medication use is prohibited in the US. All peptide-format applications are Research Use Only.
| Goal | Dose | Frequency | Route | Duration |
|---|
| Liver Support / Detox (oral capsules) | 25–50 mg | 1–2× daily before meals | Oral | 1 month |
| Prevention / Maintenance (oral capsules) | 25 mg | Once daily before breakfast | Oral | 1 month |
| Liver Support / Detox (SubQ RUO) | 0.8–2.0 mg | Once daily | SubQ | 1 month |
| Hepatic / Epithelial in-vitro studies | μM range (study-specific) | Per experimental design | In-vitro | Assay-specific |
Cycle Pattern & Pharmacokinetics
Cycle pattern: 1 month on → 4–6 months off, paralleling Epitalon, Livagen, and other Khavinson bioregulators. No formal human PK data exist. As an ultrashort tripeptide, plasma half-life is likely short (minutes to a few hours). Functional effects on hepatic and epithelial gene modulation emerge over 2–4 weeks and may persist for months post-cycle.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Oral Protocol | 25–50 mg (1–2 capsules) | 1–2x daily before meals | Oral |
| Injectable Standard | 1–2 mg | Once daily | SubQ |
| Injectable Intensive | 2 mg | Once daily | SubQ |
Peptide Interactions
Livagen is more chromatin-focused with liver/immune/EOS effects; Ovagen is liver/GI targeted. Often conceptualized together in Khavinson aging stacks.
Epitalon for pineal/circadian regulation + Ovagen for liver/GI may cover multiple systemic aging axes; evidence mainly Russian and observational.
Ovagen can be part of multi-organ bioregulator protocols (liver + lung + heart + thymus) in aging/degeneration research. No rigorous interaction studies exist.
Ovagen's proposed hepatic and epithelial support may conceptually complement antioxidant or detox interventions in liver-stress research models.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Reported tolerability — Cytogen and RUO commentary report no identified serious side effects, complications, or dependence when used as directed. Rat and in-vitro studies do not report overt toxicity at tested doses.
Evidence limitations — most Ovagen studies are Russian, small sample, non-randomized, and short-term, often without placebo controls. Western validation is almost entirely absent and mechanisms remain incompletely elucidated.
Regulatory status — the FDA classifies Ovagen as a Category 2 bulk drug substance; compounded medication use is prohibited in the US. Not approved for human therapy.
Chromatin-level action — long-term systemic effects of repeated chromatin and gene-expression manipulation are not fully characterized; caution warranted with repeated cycles.
Do Not Use If:
Active or suspected malignancy (chromatin remodeling and gene activation carry unknown oncological implications)
Individual intolerance to any component
Outside a supervised, institutional research protocol (peptide-format use)
Seek Medical Attention If:
Cardiovascular symptoms: chest pain, shortness of breath, or palpitations
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Always consult a licensed physician before and during use
Quality Indicators
Verified
Sequence verification (MS)
Tripeptide sequence Glu-Asp-Leu (EDL) confirmed by mass spectrometry (MS).
Verified
HPLC purity ≥99%
Purity ≥99% in reputable peptide vials; CoA with identity, net content, and batch number.
Verified
Lyophilized powder appearance
White to off-white lyophilized powder; clear, colorless solution upon reconstitution in sterile aqueous solution.
Caution
Storage & stability
Lyophilized storage at 2–8 °C or below, protected from light and moisture; ~2 years shelf life unopened. Reconstituted solution stable up to 28 days at 2–8 °C.
CAUTION — NOT RECOMMENDED
Quality concerns
Products marketed as dietary supplements without clear peptide identity or third-party testing. Discolored or cloudy peptide solutions indicating degradation or contamination.
Reported Research Timeline
01During active course (Days 1–30) (reported in cited studies): Ovagen acts on gastrointestinal epithelial cells and — per Khavinson's classification — on ovarian tissue cells, normalizing gene expression via chromatin-level interactions. Early effects in GI function (improved motility, reduced GI discomfort) may be detectable within 1–2 weeks of the injectable protocol. Oral supplement effects emerge more gradually due to lower bioavailability.
02Weeks 4–8 post-course (reported in cited studies): GI epithelial regenerative processes continue after the active course. Improved gastric secretory function, reduced intestinal permeability markers, and better nutrient absorption have been described in Russian clinical research using GI-targeted Khavinson peptides. Hormonal balance parameters in pre/peri-menopausal subjects have been documented in some Khavinson longitudinal data.
03Months 1–3 (sustained effects) (reported in cited studies): The epigenetic normalization pattern characteristic of Khavinson peptides maintains its effect for 3–6 months post-course, consistent with the semi-annual repeat interval. GI barrier function improvements and hormonal parameter normalization persist through this window in published cohort data.
04Long-term (repeat courses) (reported in cited studies): In Khavinson longevity studies, GI bioregulator use correlated with preserved gut integrity and reduced incidence of age-related digestive disorders. Female subjects showed more stable hormonal parameters during perimenopause with repeated bioregulator cycling. All data is from Russian observational and clinical studies — independent replication is limited.
Research Citations
"
"
Research Focus
Hepatoprotection, GI Mucosal Support, Chromatin Decondensation, Cellular Aging, Detoxification
Verified Vendors Carrying Ovagen
Frequently Asked Questions
What should researchers watch for with Ovagen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Ovagen?
During active course (Days 1–30) (reported in cited studies): Ovagen acts on gastrointestinal epithelial cells and — per Khavinson's classification — on ovarian tissue cells, normalizing gene expression via chromatin-level interactions. Early effects in GI function (improved motility, reduced GI discomfort) may be detectable within 1–2 weeks of the injectable protocol. Oral supplement effects emerge more gradually due to lower bioavailability.
How is Ovagen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →